Research Papers:

Aberrant overexpression of ADAR1 promotes gastric cancer progression by activating mTOR/p70S6K signaling

Ning Dou, Shijun Yu, Xiaojuan Ye, Dong Yang, Yandong Li and Yong Gao _

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:86161-86173. https://doi.org/10.18632/oncotarget.13354

Metrics: PDF 6472 views  |   HTML 2418 views  |   ?  


Ning Dou1, Shijun Yu1, Xiaojuan Ye1, Dong Yang1, Yandong Li1,2, Yong Gao1

1Department of Oncology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, China

2Research Center for Translational Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, China

Correspondence to:

Yandong Li, email: [email protected]

Yong Gao, email: [email protected]

Keywords: ADAR1, gastric cancer, tumorigenecity, metastasis, mTOR

Received: September 23, 2016     Accepted: November 08, 2016     Published: November 15, 2016


ADAR1, one of adenosine deaminases acting on RNA, modulates RNA transcripts through converting adenosine (A) to inosine (I) by deamination. Emerging evidence has implicated that ADAR1 plays an important role in a few of human cancers, however, its expression and physiological significance in gastric cancer remain undefined. In the present study, we demonstrated that ADAR1 was frequently overexpressed in gastric cancer samples by quantitative real-time PCR analysis. In a gastric cancer tissue microarray, ADAR1 staining was closely correlated with tumor stage (P < 0.001) and N classification (P < 0.001). Functional analysis indicated that ADAR1 overexpression promoted cell proliferation and migration in vitro, whereas ADAR1 knockdown resulted in an opposite phenotypes. Furthermore, ADAR1 knockdown also inhibited tumorigenicity and lung metastasis potential of gastric cancer cells in nude mice models. Mechanistically, ADAR1 expression had a significant effect on phosphorylation level of mTOR, p70S kinase, and S6 ribosomal protein, implying its involvement in the regulation of mTOR signaling pathway. We conclude that ADAR1 contributes to gastric cancer development and progression via activating mTOR/p70S6K/S6 ribosomal protein signaling axis. Our findings suggest that ADAR1 may be a valuable biomarker for GC diagnosis and prognosis and may represent a new novel therapeutic opportunities.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 13354